KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$6.57 USD
+0.30 (4.72%)
Updated Apr 23, 2024 03:33 PM ET
After-Market: $6.68 +0.11 (1.73%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 101 - 120 ( 364 total )
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
EYSUVIS Commercial Coverage Expands Beyond 88 Million Lives
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Financial Results Reported; Reiterate Buy; Lowering PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q1: EYSUVIS Momentum Building as INVELTYS Wades Through the Pandemic
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Symphony Health EYSUVIS Sales Tracker Suggests Q1 Beat; Raising 2021 Estimates
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L